COVID-19 and diabetes mellitus: how one pandemic worsens the other
| dc.contributor.author | Azar, William S. | |
| dc.contributor.author | Njeim, Rachel | |
| dc.contributor.author | Fares, Angie H. | |
| dc.contributor.author | Azar, Nadim S. | |
| dc.contributor.author | Azar, Sami T. | |
| dc.contributor.author | El Sayed, Mazen J. | |
| dc.contributor.author | Eid, Assaad A. | |
| dc.contributor.department | Anatomy, Cell Biology, and Physiological Sciences | |
| dc.contributor.department | Internal Medicine | |
| dc.contributor.department | Emergency Medicine | |
| dc.contributor.department | Diabetes Program | |
| dc.contributor.faculty | Faculty of Medicine (FM) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T11:36:52Z | |
| dc.date.available | 2025-01-24T11:36:52Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | In light of the most challenging public health crisis of modern history, COVID-19 mortality continues to rise at an alarming rate. Patients with co-morbidities such as hypertension, cardiovascular disease, and diabetes mellitus (DM) seem to be more prone to severe symptoms and appear to have a higher mortality rate. In this review, we elucidate suggested mechanisms underlying the increased susceptibility of patients with diabetes to infection with SARS-CoV-2 with a more severe COVID-19 disease. The worsened prognosis of COVID-19 patients with DM can be attributed to a facilitated viral uptake assisted by the host’s receptor angiotensin-converting enzyme 2 (ACE2). It can also be associated with a higher basal level of pro-inflammatory cytokines present in patients with diabetes, which enables a hyperinflammatory “cytokine storm” in response to the virus. This review also suggests a link between elevated levels of IL-6 and AMPK/mTOR signaling pathway and their role in exacerbating diabetes-induced complications and insulin resistance. If further studied, these findings could help identify novel therapeutic intervention strategies for patients with diabetes comorbid with COVID-19. © 2020, Springer Science+Business Media, LLC, part of Springer Nature. | |
| dc.identifier.doi | https://doi.org/10.1007/s11154-020-09573-6 | |
| dc.identifier.eid | 2-s2.0-85088867394 | |
| dc.identifier.pmid | 32743793 | |
| dc.identifier.uri | http://hdl.handle.net/10938/28742 | |
| dc.language.iso | en | |
| dc.publisher | Springer | |
| dc.relation.ispartof | Reviews in Endocrine and Metabolic Disorders | |
| dc.source | Scopus | |
| dc.subject | Adenosine monophosphate kinase (ampk) | |
| dc.subject | Angiotensin-converting enzyme 2 | |
| dc.subject | Covid-19 | |
| dc.subject | Cytokine storm | |
| dc.subject | Diabetes mellitus | |
| dc.subject | Mechanistic target of rapamycin (mtor) | |
| dc.subject | Comorbidity | |
| dc.subject | Coronavirus infections | |
| dc.subject | Disease susceptibility | |
| dc.subject | Humans | |
| dc.subject | Pandemics | |
| dc.subject | Pneumonia, viral | |
| dc.subject | Angiotensin converting enzyme 2 | |
| dc.subject | Hydroxymethylglutaryl coenzyme a reductase kinase | |
| dc.subject | Interleukin 6 | |
| dc.subject | Mammalian target of rapamycin | |
| dc.subject | Coronavirus disease 2019 | |
| dc.subject | Disease course | |
| dc.subject | Human | |
| dc.subject | Immune response | |
| dc.subject | Lung injury | |
| dc.subject | Mtor signaling | |
| dc.subject | Pandemic | |
| dc.subject | Pathogenesis | |
| dc.subject | Prognosis | |
| dc.subject | Review | |
| dc.subject | Risk factor | |
| dc.subject | Severe acute respiratory syndrome coronavirus 2 | |
| dc.subject | Coronavirus infection | |
| dc.subject | Disease predisposition | |
| dc.subject | Immunology | |
| dc.subject | Virus pneumonia | |
| dc.title | COVID-19 and diabetes mellitus: how one pandemic worsens the other | |
| dc.type | Review |
Files
Original bundle
1 - 1 of 1